G. Pastorin et al. / Il Farmaco 60 (2005) 299–306
305
[10] B. Cacciari, G. Pastorin, G. Spalluto, Medicinal Chemistry of A2A
adenosine receptor antagonists, Current Topic Med. Chem. 3 (2003)
403–411.
[11] Y.-C. Kim, X.-D. Ji, N. Melman, J. Linden, K.A. Jacobson, Anilide
derivatives of an 8-phenylxanthine carboxylic congener are highly
potent and selective antagonists at human A2B adenosine receptors, J.
Med. Chem. 43 (2000) 1165–1172.
5.3. Computational Methodologies
All molecular modeling studies were carried out on a
6 CPU (PIV 2.0–3.0 GHz) linux cluster running under open-
All molecular modeling studies, including “FlexibleAlign-
ment” approach, have been done using Molecular Operating
Environment (MOE, version 2003.03) suite [42].
The ground state geometry of all, charged and uncharged,
docked structures was fully optimized without geometry con-
straints using RHF/3-21G(*) ab initio calculations [43].Vibra-
tional frequency analysis was used to characterize the minima
stationary points (zero imaginary frequencies). The software
package Spartan O2 was utilized for all quantum mechanical
[12] A.M. Hayallah, J. Sandoval-Ramirez, U. Reith, U. Schobert, B. Pre-
iss, B. Schumacher, J.W. Daly, C.E. Muller, 1, 8-Disubstituted xan-
thine derivatives: synthesis of potentA2B-selective adenosine receptor
antagonists, J. Med. Chem. 45 (2002) 1500–1510.
[13] E.M. Priego, J. von Frijtag Drabbe Kuenzel, A.P. Ijzerman,
M.J. Camarasa, M.J. Perez-Perez, Pyrido[2,1-f]purine-2,4-dione
derivatives as a novel class of highly potent human A3 adenosine
receptor antagonists, J. Med. Chem. 45 (2002) 3337–3344.
[14] C.E. Muller, M. Thorand, R. Qurishi, M. Dieckmann, K.A. Jacobson,
W.L. Padgett, J.W. Daly, Imidazo[2,1-i]purin-5-ones and related tri-
cyclic water soluble purine derivatives potent A2A and A3 adenosine
receptor antagonists, J. Med. Chem. 45 (2002) 3440–3450.
[15] A.S. Shawali, C. Parkanyi, Hydrazidoyl halides in the synthesis of
heterocycles, J. Het. Chem. 17 (1980) 833–854.
[16] A.S. Shawali, Reaction of heterocyclic compounds with nitrilimines
and their precursor, Chem. Rev. 93 (1993) 2731–2777.
Acknowledgements
[17] A.S. Shawali, A.M. Mosselhi, N.M. Tawfik, A simple one-pot synthe-
sis of novel [1,2,4]triazolo[3,4-f]purines, J. Org. Chem. 66 (2001)
4055–4057.
[18] H. Maschler, B.A. Spicer, S. Harry, Xanthine derivatives, process for
their preparation and their pharmaceutical uses, European Patent
Appl. N° 96363093,0, 1990.
[19] A.M. Mosselhi, W. Pfeiderer, X. Purines, IV. Synthesis and properties
of 8-nitro xanthine and its N-methyl derivatives, J. Het. Chem. 30
(1993) 1221–1228.
[20] G. Serchi, L. Sancio, G. Bichi, Ricerche sulle xanthine. Nota 1. Benzil
derivati della 1-3 dimetil xantina, Il Farmaco Ed Sc. X (1955) 733–
741.
We wish to thank the Regione FriuliVenezia Giulia (Fondo
2000) and the Univerrsity of Trieste (fondo 60%) for finan-
cial support. The molecular modeling work coordinated by
S. Moro has been carried out with financial support fromAsso-
ciazione Italiana per la Ricerca sul Cancro (AIRC), Milan,
and the Italian Ministry for University and Research (MIUR),
Rome, Italy. S. Moro is also grateful to Chemical Computing
Group for their scientific and technical partnership. We wish
also to thank Dr: Ken A. Jacobson and Dr Zhan-Guo Gao
(Bethesda) for biding data and helpful discussion.
[21] A.F. Hagarty, M.P. Cashman, F.L. Scott, Synthesis of aliphatic hydra-
zonoyl bromides and kinetics of their conversion into hydrazides, J.
Che. Soc. Perkin Trans. II (1972) 1381–1386.
[22] P.G. Baraldi, B. Cacciari, R. Romagnoli, G. Spalluto, A. Monopoli,
E. Ongini, K. Varani, P.A. Borea, 7-Substituted-5-amino-2-(2-furyl)-
pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine
receptor antagonists: a study on the importance of modifications at the
side chain on the activity and solubility, J. Med. Chem. 45 (2002)
115–126.
[23] U. Schwabe, T. Trost, Characterization of adenosine receptors in rat
brain by (–)[3H]N6-phenylisopropyladenosine, Naunyn Schmiede-
bergs Arch. Pharmacol. 313 (1980) 179–187.
[24] M.F. Jarvis, R. Schutz, A.J. Hutchison, E. Do, M.A. Sills, M. Will-
iams, 3H]CGS 21680, an A2 selective adenosine receptor agonist
directly labelsA2 receptors in rat brain tissue, J. Pharmacol. Exp. Ther.
251 (1989) 888–893.
[25] C.A. Salvatore, M.A. Jacobson, H.E. Taylor, J. Linden, R.G. Johnson,
Molecular cloning and characterization of the human A3 adenosine
receptor, Proc. Natl. Acad. Sci. USA 90 (1993) 10365–10369.
[26] M.E. Olah, C. Gallo-Rodriguez, K.A. Jacobson, G.L. Stiles, 125I]AB-
MECA, a high affinity radioligand for the rat A3 adenosine receptor,
Mol. Pharmacol. 45 (1994) 978–982.
[27] K.N. Klotz, J. Hessling, J. Hegler, C. Owman, B. Kull, B.B. Fredholm,
et al., Comparative pharmacology of human adenosine receptor
subtypes-characterization of stably transfected receptors in CHO
cells, Naunyn Schmiedebergs Arch. Pharmacol. 357 (1998) 1–9.
[28] K.-N. Klotz, G. Cristalli, M. Grifantini, S. Vittori, M.J. Lohse, Photo-
affinity labeling ofA1-adenosine receptors, J. Biol. Chem. 260 (1985)
14659–14664.
[29] S. Moro, G. Spalluto, F. DeFlorian, G. Pastorin, B. Cacciari,
S.K. Kim, K.A. Jacobson, Demystifying the three dimensional struc-
ture of G protein-coupled receptors (GPCRs) with the aid of molecu-
lar modelling, Chem. Commun. (Camb.) (2003) 2949–2956.
References
[1] B.B. Fredholm, A.P. Ijzerman, K.A. Jacobson, K.N. Klotz, J. Linden,
International Union of Pharmacology. XXV, Nomenclature and clas-
sification of adenosine receptors, Pharmacol. Rev. 53 (2001) 527–
552.
[2] K.A. Jacobson, L.J.S. Knutsen, P1 and P2 purine and pyrimidine
receptor ligands, in: Handbook of Experimental Pharmacology, 2001,
pp. 129–175 151/1 (purinergic and pyrimidinergic Signalling I).
[3] D. van Calker, M. Mueller, B. Hamprecht, Adenosine regulates via
two different type of receptors, the accumulation of cyclic AMP in
cultured brain cells, J. Neurochem. 33 (1979) 999–1005.
[4] C. Londos, D.M.F. Cooper, J. Wolff, Subclasses of external adenosine
receptors, Proc. Natl. Acad. Sci. USA 77 (1980) 2551–2554.
[5] J.W. Daly, P. Butts-Lamb, W. Padgett, Subclasses of adenosine recep-
tors in the central nervous system: interaction with caffeine and
related methylxanthines, Cell. Mol. Neurobiol. 3 (1983) 69–80.
[6] P.G. Baraldi, B. Cacciari, R. Romagnoli, S. Merighi, K. Varani,
P.A. Borea, G. Spalluto, A3 Adenosine receptor ligands: history and
perspectives, Med. Res. Rev. 20 (2000) 103–128.
[7] I. Feoktistov, I. Biaggioni, Adenosine A2B receptors, Pharmacol. Rev.
49 (1997) 381–402.
[8] R. Volpini, S. Costanzi, S. Vittori, G. Cristalli, K.N. Klotz, Medicinal
chemistry and pharmacology of A2B adenosine receptors, Current
Topic Med. Chem. 3 (2003) 427–443.
[9] K.A. Jacobson, F. Suzuki, Recent developments in selective agonists
and antagonists acting at purine and pyrimidine receptors, Drug Dev.
Res. 39 (1996) 289–300.